MedTrace Logo

Bezlotoxumab - in "Real Life" - During the First Episode of Clostridium Difficile Infection in Patients With High Risk of Recurrence.

NCT04075422 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 869

Last updated 2023-06-26

No results posted yet for this study

Summary

The main hypothesis of the study is that Bezlotoxumab is well tolerated and effective in reducing the recurrence of ICD (Clostridium Difficile infection) in patients with a high risk of recurrence in the first episode of ICD.

As a consequence, the number of readmissions and hospital stays, will be reduced in patients treated with Bezlotoxumab.

Conditions

  • Clostridium Difficile Infection

Interventions

DRUG

Bezlotoxumab Injection [Zinplava]

Treatment with bezlotoxumad according to the routine clinical practices

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2021-08-05
Completion
2022-10-28

Countries

  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04075422 on ClinicalTrials.gov